[三季报]润丰股份(301035):润丰股份2023年第三季度报告（英文版）
|
时间：2023年10月31日 18:49:56 中财网 |
|
原标题:润丰股份:润丰股份2023年第三季度报告（英文版）
Stock code: 301035 Stock abbreviation: Rainbow Chemical Announcement No.: 2023-064 SHANDONG WEIFANG RAINBOW CHEMICAL CO.,LTD
The Third Quarter Report of 2023
The Company and all members of the Board of Directors warrant that the contents of the Quarterly Report are true, accurate and
complete, without false records, misleading statements or major omissions.
Important notes:
1. The Board of Directors, Board of Supervisors, directors, supervisors and senior management warrant that the contents of the
Quarterly Report are true, accurate and complete, without false records, misleading statements or major omissions, and shall bear
individual and collective legal liabilities.
2. The legal representative of the Company, the chief accountant in charge, and the chief of the accounting institution (accounting
supervisor), stated that the financial report in the Quarterly Report is true, accurate and complete.
3. Whether the Third Quarter Report is audited
□ Yes ? No
I. Key Financial Data
(I) Key accounting data and financial indexes
Whether the Company needs to retroactively adjust or restate the accounting data of previous years □ Yes ? No
| | Q3 2023 | Year-on-year increase
or decrease | From the start of 2023
to the end of Q3 2023 | Year-on-year increase
or decrease | | Operating income
(RMB) | 3,475,391,281.15 | -15.99% | 8,518,893,985.17 | -28.51% | | Net profit attributable
to shareholders of the
Company (RMB) | 297,230,701.58 | -28.93% | 721,621,504.36 | -44.74% | | Net profit attributable
to shareholders of the
Company excluding
non-recurring gains
and losses (RMB) | 296,836,814.30 | -29.25% | 716,335,101.21 | -45.43% | | Net cash flow from
operating activities
(RMB) | -- | -- | -246,078,338.95 | -111.63% | | Basic earnings per
share (RMB/Share) | 1.07 | -29.61% | 2.60 | -45.26% | | Diluted earnings per
share (RMB/Share) | 1.06 | -29.80% | 2.58 | -45.45% | | Weighted average
return on net assets | 4.68% | -2.51% | 11.42% | -12.51% | | | End of Q3 2023 | End of 2022 | Year-on-year increase or decrease | | | Total assets (RMB) | 14,228,247,904.23 | 11,598,874,181.42 | 22.67% | | | Equity attributable to
shareholders of the
Company (RMB) | 6,504,920,188.55 | 6,184,265,166.56 | 5.19% | |
(II) Items and amounts of non-recurring gains and losses
? Applicable □ Not applicable
| Item | Amount of Q3 2023 | Amount from the start of
2023 to the end of Q3 2023 | Notes | | Gain and loss on disposal of
non-current assets (including
the write-off portion of asset
impairment provision) | 17,577.08 | -3,080,973.27 | | | Government subsidies
included in current gains and
losses (closely related to
normal operational business
of the Company, excluding
the continuous government
subsidies of certain amount
or quota complying with
national policies) | 1,104,399.55 | 6,695,597.76 | | | Profits and losses in fair value | 32,909.02 | 100,467.38 | |
| from trading financial assets
and trading financial
liabilities, as well as
investment income from
disposal of trading financial
assets, trading financial
liabilities, and financial assets
available for sale, except for
effective hedging business
related to the normal
operation of the Company | | | | | Other non-operating revenue
and expenditure other than
those mentioned above | -687,097.64 | 1,732,957.74 | | | Less: Affected amount of
income tax | 6,273.09 | 148,651.93 | | | Affected amount of
minority shareholders'
equity (after tax) | 67,627.64 | 12,994.53 | | | Total | 393,887.28 | 5,286,403.15 | -- |
Other gains and losses items that meet the definition of non-recurring gains and losses: □ Applicable ? Not applicable
There are no other gains and losses items of the Company that meet the definition of non-recurring gains and losses.
Reasons for the non-recurring profit and loss items listed in Explanatory Announcement on Information Disclosure for Companies
Offering Their Securities to the Public No.1 - Non-recurring Gains and Losses recognized as recurring gains and losses items
□ Applicable ? Not applicable
There is no circumstance where the non-recurring profit and loss items listed in Explanatory Announcement on Information
Disclosure for Companies Offering Their Securities to the Public No.1 - Non-recurring Gains and Losses are recognized as recurring
gains and losses items.
(III) Changes to key accounting data and financial indexes and reasons ? Applicable □ Not applicable
1. Balance sheet items
Unit: RMB
| Item | September 30, 2023 | December 31, 2022 | Change (%) | Reason for change | | Pre-payments | 178,838,899.86 | 75,294,804.30 | 137.52% | Mainly due to the increase in prepayment for
purchasing raw materials during the reporting
period | | Other receivables | 48,246,140.24 | 33,525,890.70 | 43.91% | Mainly due to the increase in reserve fund for
business travels during the reporting period | | Inventory | 2,950,638,881.55 | 1,657,230,533.12 | 78.05% | Mainly due to the increase in local inventory of
some overseas subsidiaries during the reporting
period | | Other current assets | 444,183,849.66 | 184,823,557.40 | 140.33% | Mainly due to the increase in input tax credit of
subsidiaries and in prepaid taxes during the
reporting period | | Other non-current
assets | 109,793,027.67 | 69,616,034.81 | 57.71% | Mainly due to the increase in payment for
construction projects during the reporting
period |
| Short-term loan | 1,758,518,957.06 | 404,206,509.66 | 335.05% | Mainly due to the increase in bank borrowings
during the reporting period | | Accounts payable | 1,232,792,267.87 | 753,042,513.89 | 63.71% | Mainly due to the increase in credit purchases
during the reporting period | | Contract liability | 98,164,136.73 | 46,035,630.83 | 113.24% | Mainly due to the increase in advance payments
from customers during the reporting period | | Lease liability | 12,739,026.34 | 8,595,962.05 | 48.20% | Mainly due to the increase in office leasing
caused by the establishment of more new
overseas subsidiaries during the reporting
period |
2. Income statement items
Unit: RMB
| Item | January-September 2023 | January-September
2022 | Change (%) | Reason for change | | Operating cost | 6,591,428,361.19 | 9,425,611,062.95 | -30.07% | Mainly due to the decrease in cost due to the
price decrease of most of the active
pharmaceutical ingredient products during the
reporting period | | Financial expenses | -46,575,991.60 | -436,359,035.46 | 89.33% | Mainly due to the decrease in exchange gains
caused by the fluctuation of exchange rates
during the reporting period | | Investment returns | -228,488,390.61 | -60,492,810.75 | -277.71% | Mainly due to investment losses from disposal
of derivative financial assets during the
reporting period | | Income from
changes in fair
value | 53,774,061.86 | -399,356,767.11 | -113.47% | Mainly due to changes in the fair value of
derivative financial assets during the reporting
period | | Credit impairment
losses | -43,601,963.15 | -80,290,630.61 | 45.69% | Mainly due to credit impairment losses on
accounts receivable during the reporting period | | Asset impairment
losses | 486,336.57 | 1,738,356.82 | -72.02% | Mainly due to the reserve for the decline of
inventories during the reporting period | | Gains from asset
disposal | 850,034.53 | 126,624.97 | 571.30% | Mainly due to the increase in income from
disposal of non-current assets during the
reporting period | | Non-operating
income | 11,943,433.62 | 23,203,007.30 | -48.53% | Mainly due to losses from scrapping of non-
current assets during the reporting period | | Income tax
expenses | 113,258,125.87 | 201,047,731.59 | -43.67% | Mainly due to the decrease in profits during the
reporting period |
3. Cash flow statement items
Unit: RMB
| Item | January-September
2023 | January-September
2022 | Change (%) | Reason for change | | Net cash flow from
operating activities | -246,078,338.95 | 2,115,819,098.24 | -111.63% | Mainly due to the decrease in cash received
from the sale of goods and the provision of
services | | Net cash flow in investment
activities | -641,070,393.53 | -194,536,750.54 | -229.54% | Mainly due to investment expenditures in
new and continued construction projects | | Net cash flow from
financing activities | 411,177,977.26 | -1,278,718,840.25 | 132.16% | Mainly due to the increase in cash received
from bank borrowings |
II. Shareholder Information
(I) The number of common shareholders, the number of preferred shareholders whose voting rights have
been restored and the shareholdings of the top ten shareholders Unit: Share
| Number of common shareholders as
of the end of Q3 2023 | 6,260 | Number of preferred shareholders whose voting
rights have been restored as of the end of Q3 2023
(if any) | 0 | | | | | Shareholding of the top ten shareholders | | | | | | | | Shareholder name | Shareholder
nature | Shareholding
ratio | Shareholding
quantity | Quantity of
restricted
shares held | Pledge, mark or freeze | | | | | | | | Share status | Quantity | | Shandong Rainbow
Investment Co., Ltd. | Domestic non-
state-owned
legal person | 41.47% | 114,911,237 | 114,911,237 | Pledge | 22,880,000 | | KONKIA INC | Overseas legal
person | 22.08% | 61,191,800 | 61,191,800 | | | | Shandong Rainbow
Agriculture
Investment Co., Ltd. | Domestic non-
state-owned
legal person | 4.73% | 13,105,690 | 13,105,690 | | | | Orient Securities
Company Limited -
Zhonggeng Value
Pioneer Equity
Securities
Investment Fund | Other | 3.46% | 9,590,684 | 0 | | | | Industrial and
Commercial Bank of
China Co., Ltd. -
BOCOM Schroder
Trend Priority Hybrid
Securities
Investment Fund | Other | 3.22% | 8,927,604 | 0 | | | | Jinan Xinbo
Investment Co., Ltd. | Domestic non-
state-owned
legal person | 2.83% | 7,840,686 | 0 | Pledge | 6,827,700 | | Pei Xubo | Domestic
natural person | 2.81% | 7,799,613 | 0 | | | | China Merchants
Bank Co., Ltd. -
BOCOM Schroder
Qicheng Hybrid
Securities
Investment Fund | Other | 1.08% | 3,004,957 | 0 | | | | Yuanxin (Zhuhai)
Private Equity Fund
Management Co.,
Ltd. - Yuanxin China
Value Growth No. 9
Private Securities
Investment Fund | Other | 0.56% | 1,548,824 | 0 | | | | China Construction
Bank Corporation -
Guotai Great Health
Equity Securities | Other | 0.53% | 1,461,288 | 0 | | |
| Investment Fund | | | | | | | | Shareholding of top ten shareholders of unrestricted shares | | | | | | | | Shareholder name | Quantity of unrestricted shares held | Type and quantity of shares | | | | | | | | Type | Quantity | | | | | Orient Securities Company Limited -
Zhonggeng Value Pioneer Equity
Securities Investment Fund | 9,590,684 | RMB-denominated
common shares | 9,590,684 | | | | | Industrial and Commercial Bank of
China Co., Ltd. - BOCOM Schroder
Trend Priority Hybrid Securities
Investment Fund | 8,927,604 | RMB-denominated
common shares | 8,927,604 | | | | | Jinan Xinbo Investment Co., Ltd. | 7,840,686 | RMB-denominated
common shares | 7,840,686 | | | | | Pei Xubo | 7,799,613 | RMB-denominated
common shares | 7,799,613 | | | | | China Merchants Bank Co., Ltd. -
BOCOM Schroder Qicheng Hybrid
Securities Investment Fund | 3,004,957 | RMB-denominated
common shares | 3,004,957 | | | | | Yuanxin (Zhuhai) Private Equity Fund
Management Co., Ltd. - Yuanxin China
Value Growth No. 9 Private Securities
Investment Fund | 1,548,824 | RMB-denominated
common shares | 1,548,824 | | | | | China Construction Bank Corporation -
Guotai Great Health Equity Securities
Investment Fund | 1,461,288 | RMB-denominated
common shares | 1,461,288 | | | | | Hong Kong Securities Clearing
Company Ltd. | 1,332,438 | RMB-denominated
common shares | 1,332,438 | | | | | Yuanxin (Zhuhai) Private Equity Fund
Management Co., Ltd. - CITIC Capital
China Value Growth No. 1 Private
Securities Investment Fund | 1,155,045 | RMB-denominated
common shares | 1,155,045 | | | | | Guotai Asset Management Co., Ltd. -
Social Security Fund 421 Portfolio | 1,136,866 | RMB-denominated
common shares | 1,136,866 | | | | | Explanation of the above-mentioned shareholder
relationship or concerted action | 1. Shandong Rainbow Investment Co., Ltd., KONKIA INC and
Shandong Rainbow Agriculture Investment Co., Ltd. are enterprises
controlled by Wang Wencai, Sun Guoqing and Qiu Hongbing, the
actual controllers of the Company.
2. Apart from that, the Company does not know whether the top ten
shareholders and top ten shareholders of unrestricted shares are
associated or are persons acting in concert under the Measures for
the Administration of the Takeover of Listed Companies. | | | | | | | Engagement of the top 10 shareholders in securities
margin trading business (if any) | As of the end of this reporting period:
1. Pei Xubo holds 5,877,311 shares through the customer credit
transaction guarantee securities account of securities company;
2. Yuanxin (Zhuhai) Private Equity Fund Management Co., Ltd. -
Yuanxin China Value Growth No. 9 Private Securities Investment
Fund holds 1,548,824 shares through the customer credit trading
guarantee securities account of security company;
3. Yuanxin (Zhuhai) Private Equity Fund Management Co., Ltd. -
CITIC Capital China Value Growth No. 1 Private Securities Investment
Fund holds 155,000 shares through the customer credit transaction
guarantee securities account of security company. | | | | | |
(II) The number of preferred shareholders of the Company and the shareholdings of the top ten preferred
shareholders
□ Applicable ? Not applicable
(III) Changes in restricted shares
□ Applicable ? Not applicable
III. Other Important Matters
□ Applicable ? Not applicable
IV. Quarterly Financial Statements
(I) Financial statements
1. Consolidated balance sheet
Prepared by: Shandong Weifang Rainbow Chemical Co., Ltd.
September 30, 2023
Unit: RMB
| Item | September 30, 2023 | January 1, 2023 | | Current assets: | | | | Monetary funds | 3,502,488,026.65 | 3,793,952,509.17 | | Deposit reservation for balance | | | | Lending to banks and other financial institutions | | | | Financial assets held for trading | 6,000,000.00 | 8,542,688.56 | | Derivative financial assets | | | | Notes receivable | 55,864,770.98 | 59,112,584.14 | | Accounts receivable | 4,156,296,823.04 | 3,201,703,461.53 | | Receivables financing | 1,058,894.00 | 680,000.00 | | Pre-payments | 178,838,899.86 | 75,294,804.30 | | Premium receivable | | | | Re-insurance accounts receivable | | | | Reserves for re-insurance contract receivable | | | | Other receivables | 48,246,140.24 | 33,525,890.70 | | Including.: Interest receivable | | | | Dividends receivable | | | | Financial assets purchased under resale agreement | | | | Inventory | 2,950,638,881.55 | 1,657,230,533.12 | | Contracted assets | | | | Assets held for sale | | | | Non-current assets that mature within one year | | | | Other current assets | 444,183,849.66 | 184,823,557.40 | | Total current assets | 11,343,616,285.98 | 9,014,866,028.92 | | Non-current assets: | | | | Disbursed loans and advances | | | | Debt investments | | | | Other debt investment | | | | Long-term receivables | | |
| Long-term equity investment | 1,340,768.22 | 1,669,386.12 | | Other equity instrument investment | | | | Other non-current financial assets | | | | Investment real estate | 8,668,227.79 | 9,136,334.57 | | Fixed assets | 1,951,308,387.59 | 1,691,830,176.47 | | Construction in progress | 364,946,441.64 | 360,840,138.91 | | Productive biological assets | | | | Oil and gas assets | | | | Assets with rights of use | 16,209,020.94 | 15,379,959.49 | | Intangible assets | 217,541,129.67 | 226,245,165.26 | | Development expenditure | | | | Goodwill | 94,866,025.56 | 94,866,025.56 | | Long-term deferred expenses | 27,318,987.35 | 31,898,939.40 | | Deferred income tax assets | 92,639,601.82 | 82,525,991.91 | | Other non-current assets | 109,793,027.67 | 69,616,034.81 | | Total non-current assets | 2,884,631,618.25 | 2,584,008,152.50 | | Total assets | 14,228,247,904.23 | 11,598,874,181.42 | | Current liabilities: | | | | Short-term loan | 1,758,518,957.06 | 404,206,509.66 | | Borrowings from the central bank | | | | Borrowing from banks and financial institutions | | | | Financial liabilities held for trading | | | | Derivative financial liabilities | 63,418,370.94 | 122,183,523.97 | | Notes payable | 3,796,759,622.02 | 3,367,152,536.58 | | Accounts payable | 1,232,792,267.87 | 753,042,513.89 | | Advance receipts | | 254,920.26 | | Contract liability | 98,164,136.73 | 46,035,630.83 | | Financial assets sold for repurchase | | | | Deposits and interbank deposits received | | | | Amount received from agency trading of securities | | | | Amount received from agency underwriting of
securities | | | | Payroll payable | 154,907,267.17 | 191,738,722.30 | | Taxes payable | 132,101,081.27 | 106,896,314.07 | | Other payables | 51,324,022.78 | 43,899,535.81 | | Including: Interests payable | | | | Dividends payable | | | | Charges and commissions payable | | | | Re-insurance accounts payable | | | | Liabilities held for sale | | | | Non-current liabilities due within one year | 12,921,281.56 | 21,399,902.40 | | Other current liabilities | 58,419,518.22 | 59,862,778.90 | | Total current liabilities | 7,359,326,525.62 | 5,116,672,888.67 | | Non-current liabilities: | | | | Provision for insurance contracts | | | | Long-term loan | 12,840,802.47 | 17,176,777.87 | | Bonds payable | | | | Including: Preferred shares | | | | Perpetual bonds | | | | Lease liability | 12,739,026.34 | 8,595,962.05 | | Long-term payables | | | | Long-term payroll payable | | | | Accrued liabilities | | | | Deferred income | 12,224,307.69 | 13,755,569.25 | | Deferred income tax liabilities | 64,079,380.79 | 55,449,975.77 | | Other non-current liabilities | | |
| Total non-current liabilities | 101,883,517.29 | 94,978,284.94 | | Total liabilities | 7,461,210,042.91 | 5,211,651,173.61 | | Owner’s equity: | | | | Share capital | 277,115,744.00 | 277,115,744.00 | | Other equity instruments | | | | Including: Preferred shares | | | | Perpetual bonds | | | | Capital reserve | 2,337,590,533.98 | 2,301,293,600.92 | | Less: Treasury stock | | | | Other comprehensive income | 3,527,842.62 | 5,821,782.13 | | Special reserve | 36,280,194.42 | 19,551,007.62 | | Surplus reserve | 158,674,657.07 | 158,674,657.07 | | General risk reserve | | | | Undistributed profit | 3,691,731,216.46 | 3,421,808,374.82 | | Total owners' equity attributed to parent company | 6,504,920,188.55 | 6,184,265,166.56 | | Minority shareholder’s interest | 262,117,672.77 | 202,957,841.25 | | Total owner’s equity | 6,767,037,861.32 | 6,387,223,007.81 | | Total liabilities and owners’ equity | 14,228,247,904.23 | 11,598,874,181.42 |
Legal Representative: Chief Accountant in Charge: Chief of Accounting Institution: Wicky Wang Xing Bingpeng Zhang Baolin
2. Consolidated income statement from the start of 2023 to the end of Q3 2023 Unit: RMB
| Item | Amount incurred in Q3 2023 | Amount incurred in Q3 2022 | | I. Gross Operating Income | 8,518,893,985.17 | 11,915,662,694.56 | | Including: Operating income | 8,518,893,985.17 | 11,915,662,694.56 | | Interest income | | | | Premium earned | | | | Handling charges and commissions
income | | | | II. Total Operating Costs | 7,417,203,067.22 | 9,822,444,784.16 | | Including: Costs of business | 6,591,428,361.19 | 9,425,611,062.95 | | Interest expenses | | | | Handling charges and commission
expenses | | | | Surrender value | | | | Net payments for insurance claims | | | | Net withdrawal of reserve for insurance
responsibility contracts | | | | Expenditures of policy dividend | | | | Re-insurance expense | | | | Taxes and surcharges | 38,950,885.80 | 32,485,279.48 | | Sales expenses | 234,290,589.90 | 188,674,684.79 | | Management expenses | 358,656,911.50 | 308,254,477.92 | | R&D expenditures | 240,452,310.43 | 303,778,314.48 | | Financial expenses | -46,575,991.60 | -436,359,035.46 | | Including: Interest expenses | 48,622,622.61 | 12,752,415.52 | | Interest income | 41,169,941.04 | 23,243,044.73 |
| Add: Other incomes | 6,025,597.76 | 4,853,353.35 | | Income from investment (“－” for loss) | -228,488,390.61 | -60,492,810.75 | | Including: Income from investment in
associated enterprises and joint
ventures | -328,617.90 | -85,804.37 | | Income recognized at
termination of financial
assets measured at
amortized cost | | | | Foreign exchange gain ("-" fro loss) | | | | Net exposure hedging income ("-" for loss) | | | | Income from changes in fair value ("-" for loss) | 53,774,061.86 | -399,356,767.11 | | Credit impairment losses ("-" for loss) | -43,601,963.15 | -80,290,630.61 | | Asset impairment losses ("-" for loss) | 486,336.57 | 1,738,356.82 | | Gains from asset disposal ("-" for loss) | 850,034.53 | 126,624.97 | | III. Operating Profit ("-" for loss) | 890,736,594.91 | 1,559,796,037.07 | | Add: Non-operating income | 10,413,134.78 | 10,303,761.73 | | Less: Non-operating expenses | 11,943,433.62 | 23,203,007.30 | | IV. Total Profit Before Tax (“-” for total losses) | 889,206,296.07 | 1,546,896,791.50 | | Less: Income tax expenses | 113,258,125.87 | 201,047,731.59 | | V. Net Profit ("-" for net loss) | 775,948,170.20 | 1,345,849,059.91 | | (I) Classification by business continuity | | | | 1. Net profit from continuing operations (“-” for
net loss) | 775,948,170.20 | 1,345,849,059.91 | | 2. Net profit from discontinued operations (“-”
for net loss) | | | | (II) Classification by ownership | | | | 1. Net profit attributable to shareholders of the
parent company (net loss marked with "-") | 721,621,504.36 | 1,305,889,184.58 | | 2. Profit and loss of minority shareholders (net
loss marked with "-") | 54,326,665.84 | 39,959,875.33 | | VI. Net Amount after Tax of Other Comprehensive
Income | 7,917,823.34 | 3,712,236.45 | | Net amount of other comprehensive income after
tax attributed to the owners of parent company | -2,293,939.51 | 3,602,015.69 | | (I) Other comprehensive income that cannot be
reclassified into profit or loss | | | | 1. Changes due to re-measurement on
defined benefit plan | | | | 2. Other comprehensive income that cannot
be converted into profit and loss under the
equity method | | | | 3. Changes in fair value of other equity
instrument investments | | | | 4. Changes in the fair value of the credit risk of
the enterprise | | | | 5. Other | | | | (ii) Other comprehensive income that will be
reclassified into profit and loss | -2,293,939.51 | 3,602,015.69 | | 1. Other comprehensive income that can be
converted to profit or loss under the equity
method | | | | 2. Changes in fair value for other investment | | |
|
